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doi:10.1016/j.jfma.2011.04.005Background/Purpose: This prospective study aimed to describe the clinical features, as well as
outcomes, of adult patients with influenza of different severity, and to determine the predic-
tors for development of complications.
Methods: From December 2006 to March 2009, four types of diagnostic tests were given to both
in- and outpatients with influenza-like illness (ILI). Confirmed cases were categorized into
three groups (uncomplicated, moderately complicated, and severely complicated) for analysis
using a proportional odds logistic regression model.
Results: A total of 206 laboratory-confirmed cases of influenza were identified out of 360
enrolled patients with ILI. Among 30 patients (14.6%) classified as complicated cases due to
development of pneumonia (nZ 28) and viral encephalopathy (nZ 2), 16 were hospitalized
in general wards (moderately complicated) and 14 required admission to intensive care units
(severely complicated). Complicated patients were less likely to have classic symptoms of
ILI than uncomplicated patients. By multivariate analysis, the presence of coronary artery
disease, systemic corticosteroid use, impaired renal function and delayed hospital visit were
independently associated with development of complications.
Conclusion: Our study results may help clinicians to identify patients at high risk for compli-
cated influenza, to provide timely antiviral therapy and optimal clinical care.
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Table 1 Complications and outcomes in patients with
influenza according to disease severity.
Character No. of patients (%)
Uncomplicated
(nZ 176)
Complicated (nZ 30)
Moderately
(nZ 16)
Severely
(nZ 14)
Complication
Pneumonia 0 15 (93.8%) 13 (92.9%)
Encephalopathy 0 1 (6.3%) 1 (7.1%)
Shock 0 0 9 (64.3%)
Mechanical
ventilation
0 0 12 (85.7%)
Bloodstream
infection
0 0 3 (21.4%)
Outcome
LOS (d) 0 13.2 13.5 31.8 24.4
Death 0 0 2
LOSZ length of hospital stay.
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Influenza is currently the greatest pandemic disease threat
to humankind and places a large burden on healthcare
providers and society.1,2 Influenza virus infection represents
a spectrum of clinical manifestations with varying disease
severity. Although the majority of people have a self-limited
disease course, influenza can lead to complications ranging
from pneumonia to severe respiratory failure or even death
in certain susceptible hosts.3,4 Efforts have been made to
clarify the risk factors for development of complications, to
formulate vaccination policy and initiate prompt introduc-
tion of antiviral therapy for target populations.5,6 However,
most studies have focused on comparisons between hospi-
talized patients testing positive for influenza and those
testing negative, by using retrospective study designs.7,8
Limited data are available to elucidate the differences in
clinical presentations between adult patients with influenza
virus infection of different severity. Prospective studies to
determine the risk factors for complicated influenza have
been rare.
In this prospective observational study, we evaluated
the clinical characteristics and outcomes of in- and outpa-
tients with laboratory-confirmed influenza virus infection,
with an emphasis on the predictors of development of
complications.
Patients and methods
Study population and setting
A hospital-wide surveillance program for influenza-like
illness (ILI) was conducted during three consecutive influ-
enza seasons (2006e2009) at National Taiwan University
Hospital (NTUH); a 2200-bed major teaching hospital in
Northern Taiwan that provides both primary and tertiary
medical care. This study was approved by the Ethical
Committee of NTUH. After obtaining informed consent, we
enrolled all patients aged 16 years or older who visited our
outpatient clinics or emergency department, or who were
hospitalizedwith ILI defined as sudden onset of fever 38 C
with any respiratory symptom plus any of the following:
myalgia, headache, or general malaise. A standardized case
record form was used to collect patient data including
demographics, comorbidity, clinical presentation and
course, use of antiviral agents, and laboratory and radio-
logical findings. On the first hospital visit, we obtained:
nasopharyngeal swabs for the QuickVue Influenza Aþ B
rapid test (Quidel, San Diego, CA, USA); throat swabs for
viral real-time reverse transcriptase polymerase chain
reaction (RT-PCR) and virus isolation; and serum for serology
testing using a commercial kit (EUROIMMUN, Lubeck,
Germany). Based on recommendations by local health
authorities, antiviral treatment would be considered for
laboratory-confirmed or suspected cases of complicated
influenza. For patients with uncomplicated diseases, anti-
viral drugs would be given if the disease was confirmed by
laboratory tests or if the patients met the ILI criteria and
agreed to pay the medication fee by themselves.
A confirmed case of influenza was defined as one having
ILI with positivity for at least one of the following methods:virus isolation, RT-PCR, rapid influenza diagnostic test or
seroconversion of specific antibodies to influenza virus.
Patients were classified as complicated cases if hospitali-
zation was required due to development of pneumonia,
neurological complications, invasive bacterial infection,
myocarditis or pericarditis. They were further subclassified
into the moderately complicated group if admitted to
a general ward, and severely complicated group if they
were admitted to the intensive care unit for comparison.
We considered patients as uncomplicated if no hospitali-
zation was required during the whole clinical course, due to
mild illness and absence of the above-mentioned compli-
cations of influenza.
Statistical analysis
All statistical analyses were performed with SAS version
9.1.3 software (SAS Institute, Cary, NC, USA). All confirmed
cases were categorized as uncomplicated, moderately
complicated or severely complicated. Categorical variables
were compared using c2 or Fisher’s exact test. Post-hoc
tests between these three groups were done using a modi-
fied Bonferroni method. Continuous variables were
analyzed with analysis of variance. The outcome variables
were multinomial (uncomplicated, moderately compli-
cated, severely complicated), therefore, a proportional
odds logistic regression model was used to identify the
predictors of unfavorable outcomes if the proportional odds
assumption was tenable. All parameters were tested uni-
variately first. For multivariate analyses, the stepwise
variable selection procedure was applied to obtain the
candidate final regression model. All the univariate signifi-
cant and nonsignificant but biologically relevant covariates
listed in Table 2 were put on the variable list to be selected
and the significance levels for entry and for stay were set to
 0.15. Then, with the aid of substantive knowledge, the
best final regression model was identified manually by
reducing the significance levels to 0.05 corresponding to
the chosen a level.
Table 2 Comparisons between three groups of patients with influenza and univariate analysis of the potential predictors of
development of complications, using proportional odds logistic regression model.
Parameter No. of patients (%) Post-hoc testa ORb p valueb
Uncomplicated
(nZ 176)
Complicated (nZ 30)
Moderately (nZ 16) Severely (nZ 14)
Demographics
Age 65 y* 18 (10.2%) 4 (25%) 4 (28.6%) Group 1 vs. 2
Group 1 vs. 3
3.18 0.02
Male sex 94 (53.4%) 10 (62.5%) 6 (42.9%) 0.96 0.93
Underlying diseases
Any* 43 (24.3%) 10 (75%) 12 (85.2%) Group 1 vs. 2
Group 1 vs. 3
12.50 < 0.0001
DM* 7 (4%) 5 (31.3%) 4 (28.6%) Group 1 vs. 2
Group 1 vs. 3
8.75 < 0.0001
Hypertension* 14 (8%) 8 (50%) 5 (35.7%) Group 1 vs. 2
Group 1 vs. 3
7.66 < 0.0001
CAD* 2 (1.1%) 3 (18.8%) 3 (21.4%) Group 1 vs. 2
Group 1 vs. 3
14.69 0.0001
CVA 2 (1.1%) 1 (6.3%) 1 (7.1%) 5.73 0.07
Chronic lung disease 16 (9.1%) 3 (18.8%) 1 (7.1%) 1.45 0.54
Chronic renal disease* 0 (1%) 2 (12.5%) 1 (7.1%) Group 1 vs. 2 17.09 0.01
Liver cirrhosis* 2 (1.1%) 0 2 (14.3%) Group 1 vs. 3 9.66 0.02
Malignancy* 10 (5.7%) 4 (25%) 4 (28.6%) Group 1 vs. 2
Group 1 vs. 3
5.80 0.0006
Corticosteroid use* 10 (5.7%) 1 (6.3%) 6(42.9%) Group 1 vs. 3
Group 2 vs. 3
6.44 0.0003
Influenza vaccination 11 (6.3%) 0 0 < 0.001 0.97
Days from fever to
hospital visit
2.6 2.2 4.4 2.3 5.8 5.1 Group 1 vs. 2
Group 1 vs. 3
1.32 < 0.0001
Oseltamivir use 56 (31.8%) 5 (31.3%) 7(50%) 1.48 0.33
Days from fever to
oseltamivir use*
1.5 2.2 3.8 1.9 5.3 2.8 Group 1 vs. 3 1.59 0.0006
Clinical features
Peak temperature (C) 38.9 0.8 39.1 1.2 38.9 0.7 1.30 0.30
Duration of fever, day* 3.5 2.4 5.8 2.7 10.9 6.3 Group 1 vs. 2
Group 1 vs. 3
Group 2 vs. 3
1.44 < 0.0001
Chills 149 (84.7%) 12 (75%) 11 (78.6%) 0.61 0.29
Myalgia* 162 (92%) 12 (75%) 9 (64.3%) Group 1 vs. 3 0.23 0.003
Headache* 139 (79%) 13 (81.3%) 3 (21.4%) Group 1 vs. 3
Group 2 vs. 3
0.26 0.0009
Altered consciousness* 5 (2.8%) 2 (12.5%) 9 (64.3%) Group 1 vs. 3
Group 2 vs. 3
29.51 < 0.0001
Red eye 57 (32.4%) 3 (18.8%) 3 (21.4%) 0.53 0.18
Rhinorrhea* 137 (77.8%) 9 (56.3%) 7 (50%) Group 1 vs. 3 0.32 0.006
Cough 168 (95.5%) 15 (93.8%) 12 (85.7%) 0.40 0.19
Sputum production 135 (76.7%) 8 (50%) 12 (85.7%) Group 1 vs. 2 0.66 0.34
Sore throat 132 (75%) 12 (75%) 7 (50%) 0.55 0.14
Chest pain* 56 (31.8%) 8 (50%) 8 (57.1%) 2.45 0.02
Dyspnea* 66 (37.5%) 10 (62.5%) 12 (82.7%) Group 1 vs. 3 4.74 0.0004
Abdominal pain 28 (15.9%) 4 (25%) 4 (28.6%) 1.93 0.15
Diarrhea 37 (21%) 6 (37.5%) 4 (28.6%) 1.83 0.16
Laboratory findings at first hospital visit
WBC (cells/mL) 7559 5210 6524 4038 10047 6260 1 0.45
Hb (g/dL)* 13.6 1.9 11.8 2.3 12.0 3.1 Group 1 vs. 2
Group 1 vs. 3
0.65 < 0.0001
Lymphocyte (cells/mL) 1130 957 1027 781 1418 1390 1 0.63
(continued on next page)
366 U.-I. Wu et al.
Table 2 (continued )
Parameter No. of patients (%) Post-hoc testa ORb p valueb
Uncomplicated
(nZ 176)
Complicated (nZ 30)
Moderately (nZ 16) Severely (nZ 14)
Platelet (K/mL) 185450 54552 182563 118824 150071 86022 1 0.14
AST (U/L)* 30 20 40 31 55 23 Group 1 vs. 3 1.03 0.0009
ALT (U/L) 27 30 54 44 35 22 Group 1 vs. 2 1.01 0.06
CrS 2 (mg/dL)* 3 (1.9%) 2 (13.3%) 2 (14.3%) 7.15 0.008
Na 130 (mmol/L)* 0 1/15 (6.7%) 3/14 (21.4%) Group 1 vs. 3 39.96 0.003
K 5 (mmol/L) 9 (8%) 0 4 (28.6%) Group 1 vs. 3
Group 2 vs. 3
2.29 0.17
LDH (U/L)* 371 153 515 52 913 257 Group 1 vs. 3 1.006 0.002
CK (U/L)* 163 233 448 715 603 827 Group 1 vs. 3 1.001 0.005
CRP (mg/dL)* 2.8 4.0 8.1 5.9 14.0 14.2 Group 1 vs. 2
Group 1 vs. 3
Group 2 vs. 3
1.19 < 0.0001
*p value < 0.05. Categorical variables were compared using c2 test. Continuous variables were expressed as mean standard deviation
and analyzed with analysis of variance.
ALTZ alanine aminotransferase; ASTZ aspartate aminotransferase; CADZ coronary artery disease; CKZ creatinine kinase;
CrZ creatinine; CRPZ C-reactive protein; CVAZ cerebrovascular disease; DMZ diabetes mellitus; HbZ hemoglobin; LDHZ lactate
dehydrogenase; WBCZwhite blood cell.
a Group 1: uncomplicated; group 2: moderately complicated; group 3: severely complicated. Post-hoc test was performed if results of
comparisons between the three groups were significant.
b Univariate analysis using proportional odds logistic regression among uncomplicated, moderately complicated and severely
complicated patients.
Figure 1 Proportion of complicated cases in patients with
confirmed influenza for various age groups
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During three consecutive influenza seasons between
December 2006 and March 2009, a total of 360 patients with
ILI were enrolled in our study and most of them were from
the emergency department. Two hundred and six patients
were diagnosed with influenza virus infection. The majority
of confirmed cases (nZ 174) tested positive for influenza A
virus, 31 for influenza B virus, and one for both viruses.
Complications and outcomes of confirmed cases
Among 30 patients classified with complicated influenza
virus infection, 16 were hospitalized in general wards
(moderately severely group) due to pneumonia (nZ 14)
or encephalopathy (nZ 2), and 14 required admission to
the intensive care unit (severely complicated group) due
to development of respiratory failure requiring mechan-
ical ventilation (nZ 12) and/or shock (nZ 9) (Table 1).
Blood cultures were performed for all complicated
patients at admission and 3 patients were positive for
Streptococcus pyogenes, methicillin-resistant Staphylo-
coccus aureus and Corynebacterium jeikeium respec-
tively. Overall, two patients died of septicemia and
respiratory failure on the fourth and eighth day after
onset of illness, respectively. One of them was a 37-year-
old woman without any underlying medical condition,
whereas the other was a 47-year-old male patient with
multiple myeloma who had received autologous periph-
eral blood stem cell transplantation 6 months prior to
disease onset.Factors associated with development of
complications
Compared to patients aged< 41 years, those aged 41 years
were more likely to develop complications (Fig. 1). Median
age of uncomplicated cases was 31 years, which was signifi-
cantly younger than those in the moderately complicated
group (median, 51 years) and severely complicated group
(median, 53 years). Compared with the uncomplicated
group, patients in the complicated group were more likely to
368 U.-I. Wu et al.have underlying medical conditions and systemic cortico-
steroid use (Table 2). Classic symptoms of influenza including
rhinorrhea, myalgia and headache were not frequently
reported in complicated patients, and the duration of fever
was significantly longer than in uncomplicated cases. Rhab-
domyolysis, elevated C-reactive protein level, and impair-
ment of hepatic and renal function were more frequently
detected in complicated patients at hospital presentation.
The duration from fever to hospital visit was significantly
prolonged in complicated groups. The percentage of patients
treated with antiviral agents was similar in these three
groups. However, the mean time from onset of fever to
initiation of oseltamivir treatment was significantly longer in
the complicated group compared with uncomplicated group.
None of the 30 complicated cases had received seasonal
influenza vaccination in the past year, or were able to
receive antiviral therapy within 48 hours after symptom
onset due to delay in hospital visit.
Univariate analysis using proportional odds logistic
regression was performed to identify the potential predic-
tors of development of complications in patients with influ-
enza virus infection (Table 2). In multivariate analysis,
independent factors that were significantly associated with
development of complications included coronary artery
disease [odds ratio (OR): 58.4, p< 0.0001), systemic corti-
costeroid use (OR: 12.19, pZ 0.0002), days from fever to
hospital visit (OR: 1.47, p< 0.0001) and elevation of serum
creatinine at presentation (OR: 12.41, pZ 0.0015) (Table 3).
Discussion
This prospective, observational study summarized the clin-
ical findings and laboratory characteristics of 206 adult
patients with confirmed influenza virus infection during
three influenza seasons in a large tertiary teaching hospital.
The clinical characteristics of influenza infection have
been well described for outpatients, especially children,
in previous studies.9e12 However, prospective studies to
investigate the risk factors for complications of influenza
have been rare. Data in subtropical countries are particularly
scarce. Most studies have assessed hospitalized patients as
a whole and have ignored the potential differences in
underlying pathophysiology between patients with or
without unstable hemodynamics.6,13 The present prospec-
tive, multiyear study is unique in having recruited patientsTable 3 Multivariate analysis of the predictors of devel-
opment of complicated influenza.
Covariate P value OR
CAD < 0.0001 58.40
Corticosteroid use 0.0002 12.19
Cr 2 0.0015 12.41
Days from fever to hospital visit < 0.0001 1.47
Proportional odds polychotomous logistic regression model:
nZ 206, percentage of concordant pairsZ 85.5%, percentage
of discordant pairsZ 10.5%, adjusted generalized R2Z 0.6623,
estimated area under the receiver operating characteristic
curveZ 0.896, and Pearson goodness-of-fit test p value< 0.0001
(dfZ 275). CADZ coronary artery disease; CrZ creatinine;
dfZ degrees of freedom; ORZ odds ratio.with different levels of severity and stratifying them into
three groups for analysis, thus being able to illustrate and
compare specifically their differences in clinical features.
Moreover, we provided information for primary care physi-
cians to identify patients at risk for influenza complications.
Our findings indicating that patients with advanced age
and predisposing illnesses were at increased risk of devel-
oping complications are consistent with previous studies.14,15
A finding of particular interest, which has rarely been
explored in previous studies, was the fact that systemic
corticosteroid use was associated with development of
complicated influenza. This can be attributed to slower viral
clearance in patients with corticosteroid administration, as
reported in a previous study.16 Contrary to our expectation,
chronic lung diseases were not shown to be a risk factor for
development of complications, either by univariate or
multivariate analysis. This might be related to the frequent
assumption of bacterial pneumonia when severe respiratory
symptoms developed in patients with chronic lung conditions
in our clinical settings, thereby deferring antiviral testing and
causing under-reporting of influenza among this specific
population.
Classic symptoms including fever, myalgia, chills, head-
ache, sore throat, dry cough and malaise, with sudden onset
after an incubation period of 1e2 days identify patients with
ILI but are not particularly useful for confirming or excluding
the diagnosis of influenza.17,18 In our present study, clinical
characteristics differed between patients in complicated
and uncomplicated groups. The complicated patients were
less likely to have typical symptoms of ILI. Similar findings
have been observed in previous studies.7,19,20 This might be
attributable to the presence of altered consciousness in
severely ill patients, leading to recall bias of their initial
clinical symptoms. Their atypical or more subtle clinical
presentations might also be explained by the high preva-
lence of medical comorbidity. Traditional criteria of ILI
may be more useful for detecting influenza in otherwise
healthier, outpatient populations than those having under-
lying medical conditions.
Among our study population, we did not observe any
patient who presented with mild illness at the initial visit to
the outpatient clinic or emergency department and devel-
oped complications later in their clinical course. In contrast,
all the complicated cases, on the first occasion that they
sought medical help, had more severe clinical presentations
due to delayed hospital visit. Although the proportion of
patients that received oseltamivir was relatively low in both
the complicated and uncomplicated groups, the majority of
severely ill patients had not received antiviral agents until
late in the course of their illness. Nonspecific clinical
presentations, inadequate alertness of clinicians reflected
by a low rate of oseltamivir prescription in a timely manner,
and a common misconception among the general population
that influenza is not severe might lead to failure to provide
timely medical care and antiviral treatment.
The limitations of this study should be recognized. The
source of patients was limited to a single medical center,
thereby limiting the generalizability of this study and
overestimating the complication and mortality rates. Cases
of influenza infection may have been missed if the sample
was not obtained properly or if the sample was obtained
late in the course of the disease. Conversely, false-positive
Risk factors for complications of influenza 369viral assay determinations might have contributed to
ascertainment bias. However, the positive predictive value
was expected to be high because this study was conducted
during influenza seasons only.
In conclusion, the presence of coronary artery disease,
systemic corticosteroid use, impaired renal function at
presentation, and delayed hospital visit are independently
associated with development of complications in patients
with influenza and thus warrant rapid diagnostic testing to
achieve timely antiviral treatment and infection control
measures. A high index of suspicion of influenza should be
raised during the influenza season on the basis of possible
atypical presentations in patients with underlying medical
conditions.
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